EurekaMag.com logo
+ Site Statistics
References:
53,214,146
Abstracts:
29,074,682
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Evaluation of the human cell line RPMI 2650 as an in vitro nasal model



Evaluation of the human cell line RPMI 2650 as an in vitro nasal model



Rhinology 33(4): 194-198



We have investigated a human nasal cell line, RPMI 2650 (ATCC), as an in vitro model to assess the absorption and tolerability of nasally administrated peptides. This cell line was cultured on different filters (i.e. Nunc, Costar, Falcon, Millipore, and Becton) which were uncoated or coated with collagen types I or IV, laminin, fibronectin and extracellular matrix. Cell line morphology, capability of forming a cell layer and phenotype were analyzed by light-, fluorescence- and electron microscopy. The morphological analysis showed that RPMI 2650 cells were forming cell clusters on one group of filters (i.e., Nunc, Costar, Falcon and Becton filters coated with collagen types I or IV, laminin and extracellular matrix). On the second group of filters (i.e., Becton and Millipore filters, coated with fibronectin) the cells had the tendency to spread in a cell layer. In both groups of filters, the cells never showed cell polarization, nor microvilli and tight junctions. Phenotyping of this cell line was performed by indirect immunofluorescence using monoclonal antibodies against human cytokeratins 10, 17 and 18 (markers of epithelial cells), desmin (markers of mesothelial cells) and vimentin (marker of mesothelial cells). Vimentin was strongly expressed, cytokeratins 10, 17 and 18 were weakly expressed, and desmin was not expressed. The human nasal cell line RPMI 2650 was not able to form a tight cell layer under these cell culture conditions. The limits of this cell line as an in vitro nasal model for drug absorption is discussed.

(PDF 0-2 workdays service: $29.90)

Accession: 008638150

Download citation: RISBibTeXText

PMID: 8919210



Related references

The characterization of the human nasal epithelial cell line RPMI 2650 under different culture conditions and their optimization for an appropriate in vitro nasal model. Pharmaceutical Research 32(2): 665-679, 2015

The novel use of the human nasal epithelial cell line RPMI 2650 as an in vitro model to study the influence of allergens and cytokines on transforming growth factor-beta gene expression and protein release. Clinical and Experimental Allergy 35(6): 811-819, 2005

RPMI 2650 epithelial model and three-dimensional reconstructed human nasal mucosa as in vitro models for nasal permeation studies. European Journal of Pharmaceutics and Biopharmaceutics 74(2): 290-297, 2010

Evaluation of human nasal RPMI 2650 cells grown at an air-liquid interface as a model for nasal drug transport studies. Journal of Pharmaceutical Sciences 97(3): 1165-1178, 2007

Activity of Multidrug Resistance-Associated Proteins 1-5 (MRP1-5) in the RPMI 2650 Cell Line and Explants of Human Nasal Turbinate. Molecular Pharmaceutics 14(5): 1577-1590, 2017

Cultivation of RPMI 2650 cells as an in-vitro model for human transmucosal nasal drug absorption studies: optimization of selected culture conditions. Journal of Pharmacy and Pharmacology 64(11): 1621-1630, 2013

Is RPMI 2650 a Suitable In Vitro Nasal Model for Drug Transport Studies?. European Journal of Drug Metabolism and Pharmacokinetics, 2017

Application of RPMI 2650 nasal cell model to a 3D printed apparatus for the testing of drug deposition and permeation of nasal products. European Journal of Pharmaceutics and Biopharmaceutics 107: 223-233, 2016

Retinoic acid and hydrocortisone strengthen the barrier function of human RPMI 2650 cells, a model for nasal epithelial permeability. Cytotechnology 65(3): 395-406, 2012

Two-deoxyglucose as an anti-metabolite in human carcinoma cell line RPMI-2650 and drug-resistant variants. Anticancer Research 24(2a): 433-440, 2004

Cytotoxicity of Different Excipients on RPMI 2650 Human Nasal Epithelial Cells. Molecules 21(5): -, 2016

Expression of P-glycoprotein in excised human nasal mucosa and optimized models of RPMI 2650 cells. International Journal of Pharmaceutics 508(1-2): 22-33, 2016

Production of autostimulatory growth factors by the human carcinoma line, RPMI 2650. In Vitro Cellular & Developmental Biology 29A(2): 153-160, 1993

Expression analysis of human solute carrier (SLC) family transporters in nasal mucosa and RPMI 2650 cells. European Journal of Pharmaceutical Sciences, 2018

Roles of epidermal growth factor receptor signaling pathway on cultured human nasal epithelial cells RPMI-2650. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 44(3): 203-208, 2011